Korean MFDS publishes Revision 7 of Comparative Dissolution Test Guideline
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
The Korean Ministry of Food and Drug Safety (MFDS) has revised the "Guidelines for Comparative Dissolution Test (Guideline for Civil Petitioners)". A new version (revision 7) dated 18 May 2023 was published.
The document is divided into the following main chapters:
- Overview
- Considerations when Determining the Equivalence of Comparative Dissolution Test Data
- Comparative Dissolution Test Result Report Standard Format
- References
According to the English translation of chapter 1, "the purpose of this guideline is to help applicants or reviewers understand as reference data for preparation of comparative dissolution test result reports required when applying for pharmaceutical product approval/notification (including changes). [...] This guideline is applied to items subject to comparative dissolution testing for new items for approval and notification of pharmaceuticals and items with changes in approval items."
Compared to the previous version, which was published in 2021, the new document contains additional considerations and references when determining equivalence of comparative dissolution test.
The revised guideline in Korean language can be found as a PDF file on the website of the Ministry of Food and Drug Safety.
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity


